Challenges to oligonucleotides-based therapeutics for Duchenne muscular dystrophy

Skeletal Muscle

Volumn 1, Issue 1, 2011, Pages

  Goyenvalle, Aurélie ^a   Davies, Kay E ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80055038015     PISSN: None     EISSN: 20445040     Source Type: Journal    
DOI: 10.1186/2044-5040-1-8     Document Type: Review

References (33)

1. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1978, 75:280-284. 10.1073/pnas.75.1.280, 411230, 75545.
2. Rayburn ER, Zhang R. Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?. Drug Discov Today 2008, 13:513-521. 10.1016/j.drudis.2008.03.014, 2497463, 18549978.
3. Crooke ST. Vitravene--another piece in the mosaic. Antisense Nucleic Acid Drug Dev 1998, 8:vii-viii.
4. Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2003, 2:731-740. 10.1016/S1474-4422(03)00585-4, 14636778.
5. Davies KE, Nowak KJ. Molecular mechanisms of muscular dystrophies: old and new players. Nat Rev Mol Cell Biol 2006, 7:762-773. 10.1038/nrm2024, 16971897.
6. Emery AE. The muscular dystrophies. Lancet 2002, 359:687-695. 10.1016/S0140-6736(02)07815-7, 11879882.
7. Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 1988, 2:90-95. 10.1016/0888-7543(88)90113-9, 3384440.
8. Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen GJ, den Dunnen JT. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 2009, 30:293-299. 10.1002/humu.20918, 19156838.
9. Pramono ZA, Takeshim Y, Alimsardjono H, Ishii A, Takeda S, Matsuo M. Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence. Biochem Biophys Res Commun 1996, 226:445-449. 10.1006/bbrc.1996.1375, 8806654.
10. Dunckley MG, Manoharan M, Villiet P, Eperon IC, Dickson G. Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet 1998, 7:1083-1090. 10.1093/hmg/7.7.1083, 9618164.
11. Lu QL, Mann CJ, Lou F, Bou-Gharios G, Morris GE, Xue SA, Fletcher S, Partridge TA, Wilton SD. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 2003, 9:1009-1014. 10.1038/nm897, 12847521.
12. Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, Wilton SD. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J Gene Med 2006, 8:207-216. 10.1002/jgm.838, 16285002.
13. Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, Steinhaus JP, Moulton HM, Iversen PL, Wilton SD. Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol Ther 2007, 15:1587-1592. 10.1038/sj.mt.6300245, 17579573.
14. Ivanova GD, Arzumanov A, Abes R, Yin H, Wood MJ, Lebleu B, Gait MJ. Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res 2008, 36:6418-6428. 10.1093/nar/gkn671, 2582604, 18842625.
15. Yin H, Lu Q, Wood M. Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Mol Ther 2008, 16:38-45. 10.1038/sj.mt.6300329, 17968354.
16. Yokota T, Lu QL, Partridge T, Kobayashi M, Nakamura A, Takeda S, Hoffman E. Efficacy of systemic morpholino exon-skipping in duchenne dystrophy dogs. Ann Neurol 2009, 65:667-676. 10.1002/ana.21627, 19288467.
17. van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M, den Dunnen JT, Koop K, van der Kooi AJ, Goemans NM, de Kimpe SJ, Ekhart PF, Venneker EH, Platenburg GJ, Verschuuren JJ, van Ommen GJ. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007, 357:2677-2686. 10.1056/NEJMoa073108, 18160687.
18. Gebski BL, Mann CJ, Fletcher S, Wilton SD. Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum Mol Genet 2003, 12:1801-1811. 10.1093/hmg/ddg196, 12874101.
19. Arechavala-Gomeza V, Graham IR, Popplewell LJ, Adams AM, Aartsma-Rus A, Kinali M, Morgan JE, van Deutekom JC, Wilton SD, Dickson G, Muntoni F. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum Gene Ther 2007, 18:798-810. 10.1089/hum.2006.061, 17767400.
20. Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, Guglieri M, Ashton E, Abbs S, Nihoyannopoulos P, Garralda ME, Rutherford M, McCulley C, Popplewell L, Graham IR, Dickson G, Wood MJ, Wells DJ, Wilton SD, Kole R, Straub V, Bushby K, Sewry C, Morgan JE, Muntoni F. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 2009, 8:918-928. 10.1016/S1474-4422(09)70211-X, 2755039, 19713152.
21. Goemans NM, Buyse G, Tulinius M, Vershuuren JJG, de Kimpe SJ, van Deutekom JCT. A Phase I/IIa study on antisense compound PRO051 in patients with Duchenne muscular dystrophy. Neuromuscul Disord 2009, 19:659-660.
22. Goemans NM, Tulinius M, Buyse G, Wilson R, de Kimpe R, van Deutekom JCT, Campion G. 24 week follow-up data from a phase I/IIa extension study of PRO051/GSK240220968 in subjects with Duchenne muscular dystrophy. Neuromuscul Disord 2010, 639.
23. Shrewsbury SB, Cirak S, Guglieri M, Bushby K, Muntoni F. Current progress and preliminary results with the systemic administration trial of AVI-4658, a novel phosphorodiamidate morpholino oligomer (PMO) skipping dystrophin exon 51 in Duchenne muscular dystrophy (DMD). Neuromuscul Disord 2010, 20:639-640.
24. Alter J, Lou F, Rabinowitz A, Yin H, Rosenfeld J, Wilton SD, Partridge TA, Lu QL. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 2006, 12:175-177. 10.1038/nm1345, 16444267.
25. Heemskerk HA, de Winter CL, de Kimpe SJ, van Kuik-Romeijn P, Heuvelmans N, Platenburg GJ, van Ommen GJ, van Deutekom JC, Aartsma-Rus A. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med 2009, 11:257-266. 10.1002/jgm.1288, 19140108.
26. Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J, Jadoon A, Bou-Gharios G, Partridge T. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 2005, 102:198-203. 10.1073/pnas.0406700102, 544058, 15608067.
27. Wu B, Lu P, Benrashid E, Malik S, Ashar J, Doran TJ, Lu QL. Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino. Gene Ther 17:132-140. 10.1038/gt.2009.120, 19759562.
28. Yin H, Moulton HM, Seow Y, Boyd C, Boutilier J, Iverson P, Wood MJ. Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 2008, 17:3909-3918. 10.1093/hmg/ddn293, 18784278.
29. Jearawiriyapaisarn N, Moulton HM, Sazani P, Kole R, Willis MS. Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers. Cardiovasc Res 2010, 85:444-453. 10.1093/cvr/cvp335, 2802205, 19815563.
30. Wu B, Moulton HM, Iversen PL, Jiang J, Li J, Li J, Spurney CF, Sali A, Guerron AD, Nagaraju K, Doran T, Lu P, Xiao X, Lu QL. Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci USA 2008, 105:14814-14819. 10.1073/pnas.0805676105, 2546441, 18806224.
31. Moulton HM, Moulton JD. Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim Biophys Acta 2010, 1798:2296-2303. 10.1016/j.bbamem.2010.02.012, 20170628.
32. Jearawiriyapaisarn N, Moulton HM, Buckley B, Roberts J, Sazani P, Fucharoen S, Iversen PL, Kole R. Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther 2008, 16:1624-1629. 10.1038/mt.2008.120, 2671676, 18545222.
33. Yin H, Moulton HM, Betts C, Seow Y, Boutilier J, Iverson PL, Wood MJ. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet 2009, 18:4405-4414. 10.1093/hmg/ddp395, 19692354.